Cerenome, Inc.

CNSY Healthcare Biotechnology

Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.70 0.18 −9.57%
Market cap
$14.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
3/9
Altman Z
−44.87
Beneish M
−3.46
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 3 3
ROE
40,893.33% 903.94% 204.30% (520.84%)
ROA
(191.33%) (195.02%) (74.63%) (181.53%)
ROIC
0.00% 0.00% 0.00% (532.77%)
Return on Tangible Assets
(578.27%) (719.11%) (107.62%) (479.69%)
Average Days of Receivables
0.00 22.55 95.09 152.93
Free Cash Flow per Share
(3.79) (6.69) (3.27) (3.41)
Free Cash Flow
(16.30) (20.81) (21.72) (23.55)
Other line items

Show all line items

Columns are period end dates